Anaphylactic shock depends on PI3K and eNOS-derived NO

Journal of Clinical Investigation

Volumn 116, Issue 8, 2006, Pages 2244-2251

  Cauwels, Anje ^a,d   Janssen, Ben ^b   Buys, Emmanuel ^a,c   Sips, Patrick ^a   Brouckaert, Peter ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Technologiepark 927 ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE; INDUCIBLE NITRIC OXIDE SYNTHASE; METHYLENE BLUE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE A2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; THROMBOCYTE ACTIVATING FACTOR;

ALLERGIC REACTION; ANAPHYLACTIC SHOCK; ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HYPOTENSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANAPHYLAXIS; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXADIAZOLES; PLATELET ACTIVATING FACTOR; QUINOXALINES; SERUM ALBUMIN, BOVINE; TRANSCRIPTION, GENETIC;

EID: 33746752742     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI25426     Document Type: Article

References (60)

1. Kemp, S.F., and Lockey, R.F. 2002. Anaphylaxis: a review of causes and mechanisms. J. Allergy Clin. Immunol. 110:341-348.
2. Neugut, A.I., Ghatak, A.T., and Miller, R.L. 2001. Anaphylaxis in the United States: an investigation into its epidemiology. Arch. Intern. Med. 161:15-21.
3. Brown, S.G. 2005. Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Curr. Opin. Allergy Clin. Immunol. 5:359-364.
4. Montrucchio, G., Alloatti, G., and Camussi, G. 2000. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol. Rev. 80:1669-1699.
5. Terashita, Z., Imura, Y., Nishikawa, K., and Sumida, S. 1985. Beneficial effects of (RS)-2-methoxy-3-(octadecylcarbamoyloxy)propyl 2-(3-thiazolio)ethyl phosphate, a specific PAF antagonist, in endotoxin and anaphylactic shock. Adv. Prostaglandin Thromboxane Leukot. Res. 15:715-717.
6. Sanchez-Crespo, M., Fernandez-Gallardo, S., Nieto, M.L., Baranes, J., and Braquet, P. 1985. Inhibition of the vascular actions of IgG aggregates by BN 52021, a highly specific antagonist of paf-acether. Immunopharmacology. 10:69-75.
7. Darius, H., Smith, J.B., and Lefer, A.M. 1986. Inhibition of the platelet activating factor mediated component of guinea pig anaphylaxis by receptor antagonists. Int. Arch. Allergy Appl. Immunol. 80:369-375.
8. Ishii, S., et al. 1998. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J. Exp. Med. 187:1779-1788.
9. Fukuda, Y., et al. 2000. Effect of human plasmatype platelet-activating factor acetylhydrolase in two anaphylactic shock models. Eur. J. Pharmacol. 390:203-207.
10. Takano, H., et al. 1997. Effects of aminoguanidine on systemic inflammatory response syndrome induced by platelet activating factor and by lipopolysaccharide in rats. Eur. J. Pharmacol. 323:107-110.
11. Wang, H.G., Shibamoto, T., Matsuda, Y., and Koyama, S. 1998. The role of endogenous nitric oxide in the sympathetic and hemodynamic response to platelet activating factor-induced hypotension in anesthetized dogs. Shock. 9:58-64.
12. Yoshikawa, T., et al. 1997. Role of superoxide and nitric oxide in platelet-activating factor-induced acute lung injury, hypotension, and mortality in rats. Crit. Care Med. 25:286-292.
13. Muldoon, S.M., Hart, J.L., Bowen, K.A., and Freas, W. 1988. Attenuation of endothelium-mediated vasodilation by halothane. Anesthesiology. 68:31-37.
14. Hart, J.L., et al. 1993. Effects of halothane on EDRF/cGMP-mediated vascular smooth muscle relaxations. Anesthesiology. 79:323-331.
15. Ma, J., et al. 1996. L-NNA-sensitive regional cerebral blood flow augmentation during hypercapnia in type III NOS mutant mice. Am. J. Physiol. 271:H1717-H1719.
16. Amir, S., and English, A.M. 1991. An inhibitor of nitric oxide production, NG-nitro-L-arginine-methyl ester, improves survival in anaphylactic shock. Eur. J. Pharmacol. 203:125-127.
17. Mitsuhata, H., et al. 1995. Nitric oxide synthase inhibition is detrimental to cardiac function and promotes bronchospasm in anaphylaxis in rabbits. Shock. 4:143-148.
18. Mitsuhata, H., et al. 1995. An inhibitor of nitric oxide synthase, N omega-nitro-L-arginine-methyl ester, attenuates hypotension but does not improve cardiac depression in anaphylaxis in dogs. Shock. 3:447-453; discussion 454.
19. Bellou, A., et al. 2003. Constitutive nitric oxide synthase inhibition combined with histamine and serotonin receptor blockade improves the initial ovalbumin-induced arterial hypotension but decreases the survival time in brown norway rats anaphylactic shock. Shock. 19:71-78.
20. Moncada, S. 1997. Nitric oxide in the vasculature: physiology and pathophysiology. Ann. N. Y. Acad. Sci. 811:60-67; discussion 67-69.
21. Kirkeboen, K.A., and Strand, O.A. 1999. The role of nitric oxide in sepsis-an overview. Acta Anaesthesiol. Scand. 43:275-288.
22. Murad, F. 1996. The 1996 Albert Lasker Medical Research Awards. Signal transduction using nitric oxide and cyclic guanosine monophosphate. JAMA. 276:1189-1192.
23. Ortega Mateo, A., and Amaya Aleixandre de Artiñano, M. 2000. Nitric oxide reactivity and mechanisms involved in its biological effects. Pharmacol. Res. 42:421-427.
24. Cauwels, A., Janssen, B., Waeytens, A., Cuvelier, C., and Brouckaert, P. 2003. Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2. Nat. Immunol. 4:387-393.
25. Szabo, C., et al. 1993. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ. Res. 73:991-999.
26. Lucas, K.A., et al. 2000. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 52:375-414.
27. Oliveira Neto, A.M., Duarte, N.M., Vicente, W.V., Viaro, F., and Evora, P.R. 2003. Methylene blue: an effective treatment for contrast medium-induced anaphylaxis. Med. Sci. Monit. 9:CS102-CS106.
28. Buzato, M.A., Viaro, F., Piccinato, C.E., and Evora, P.R. 2005. The use of methylene blue in the treatment of anaphylactic shock induced by compound 48/80: experimental studies in rabbits. Shock. 23:582-587.
29. Cauwels, A., et al. 2000. Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase. Immunity. 13:223-231.
30. Zingarelli, B., Hasko, G., Salzman, A.L., and Szabo, C. 1999. Effects of a novel guanylyl cyclase inhibitor on the vascular actions of nitric oxide and peroxynitrite in immunostimulated smooth muscle cells and in endotoxic shock. Crit. Care Med. 27:1701-1707.
31. Sips, P., Buys, E., Rogge, E., Dewerchin, M., and Brouckaert, P. 2005. Functional knockout of the soluble guanylate cyclase alpha1 subunit leads to gender-specific hypertension while retaining sensitivity to nitric oxide. Circulation. 112:A747.
32. Dimmeler, S., et al. 1999. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 399:601-605.
33. Fulton, D., et al. 1999. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 399:597-601.
34. Van Ummersen, L., et al. 2004. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin. Cancer Res. 10:7450-7456.
35. Granville, C.A., Memmott, R.M., Gills, J.J., and Dennis, P.A. 2006. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin. Cancer Res. 12:679-689.
36. Chen, W.S., et al. 2001. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 15:2203-2208.
37. Cho, H., et al. 2001. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 292:1728-1731.
38. Easton, R.M., et al. 2005. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol. Cell. Biol. 25:1869-1878.
39. Chen, J., et al. 2005. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat. Med. 11:1188-1196.
40. Takekoshi, K., et al. 1993. Effect of NG-nitro-L-arginine on shock induced by endotoxin and by platelet activating factor in dogs. Eur. J. Pharmacol. 250:465-467.
41. Yamada, T., Yukioka, H., Hayashi, M., Asada, A., and Inoue, M. 1998. Effects of inhaled nitric oxide on platelet-activating factor-induced pulmonary hypertension in dogs. Acta Anaesthesiol. Scand. 42:358-368.
42. Snyder, F. 1990. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am. J. Physiol. 259:C697-C708.
43. Choi, J.H., et al. 2000. Selective involvement of reactive oxygen intermediates in platelet-activating factor-mediated activation of NF-kappaB. Inflammation. 24:385-398.
44. Herbert, J.M., et al. 1993. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist. J. Lipid. Mediat. 8:31-51.
45. Fleming, I., and Busse, R. 2003. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284:R1-R12.
46. Duran, W.N., et al. 2000. Stimulation of NO production and of eNOS phosphorylation in the microcirculation in vivo. Microvasc. Res. 60:104-111.
47. Hisamoto, K., et al. 2001. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J. Biol. Chem. 276:3459-3467.
48. Cho, H., Thorvaldsen, J.L., Chu, Q., Feng, F., and Birnbaum, M.J. 2001. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276:38349-38352.
49. Peng, X.D., et al. 2003. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 17:1352-1365.
50. Szabo, C., Mitchell, J.A., Thiemermann, C., and Vane, J.R. 1993. Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br. J. Pharmacol. 108:786-792.
51. Szabo, C. 1995. Alterations in nitric oxide production in various forms of circulatory shock. New Horiz. 3:2-32.
52. Cirino, G., Fiorucci, S., and Sessa, W.C. 2003. Endothelial nitric oxide synthase: the Cinderella of inflammation? Trends Pharmacol. Sci. 24:91-95.
53. Bucci, M., et al. 2000. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat. Med. 6:1362-1367.
54. Bucci, M., et al. 2005. Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo. Proc. Natl. Acad. Sci. U. S. A. 102:904-908.
55. Vo, P.A., Lad, B., Tomlinson, J.A., Francis, S., and Ahluwalia, A. 2005. Autoregulatory role of endothelium-derived nitric oxide (NO) on lipopolysaccharide-induced vascular inducible NO synthase expression and function. J. Biol. Chem. 280:7236-7243.
56. Connelly, L., Madhani, M., and Hobbs, A.J. 2005. Resistance to endotoxic shock in endothelial nitricoxide synthase (eNOS) knock-out mice: a proinflammatory role for eNOS-derived NO in vivo. J. Biol. Chem. 280:10040-10046.
57. Alloatti, G., et al. 2003. Phosphoinositide 3-kinase gamma-deficient hearts are protected from the PAF-dependent depression of cardiac contractility. Cardiovasc. Res. 60:242-249.
58. Alloatti, G., Montrucchio, G., Lembo, G., and Hirsch, E. 2004. Phosphoinositide 3-kinase gamma: kinase-dependent and -independent activities in cardiovascular function and disease. Biochem. Soc. Trans. 32:383-386.
59. Laubach, V.E., Shesely, E.G., Smithies, O., and Sherman, P.A. 1995. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci. U. S. A. 92:10688-10692.
60. Shesely, E.G., et al. 1996. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 93:13176-13181.